The present invention is related to a conjugate comprising a structure of general formula (1) [TM1] - [AD1] - [LM] - [AD2] - [TM2] (1), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (2): wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl AA-COOH is an amino acid selected from the group consisting of 2-amino-2 adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9 carboxylic acid R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3C8)cycloalkylmethyl, halogen, nitro and trifluoromethyl ALK is (C2-C5)alkylidene R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the following formula (3) wherein ALK is (C2-C5)alkylidene R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl and R7 is a bond or a pharmacologically acceptable salt, solvate or hydrate thereof.La présente invention concerne un conjugué comprenant une structure de formule générale (1) [TM1] - [AD1] - [LM] - [AD2] - [TM2] (1), dans laquelle TM1 est une première entité de ciblage, laquelle première entité de ciblage est capable de se lier à une première cible, AD1 est une première entité dadaptateur ou est absent, LM est une entité de lieur ou est absent, AD2 est une seconde entité dadaptateur ou est absent et TM2 est une seconde entité de ciblage, dans lequel la seconde entité de ciblage est capable de se lier à une seconde cible dans lequel la première entité de ciblage et/ou la seconde entité de ci
